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Comparative effect of intraduodenal and intrajejunal glucose
infusion on the gut–incretin axis response in healthy males
T Wu1,2, SS Thazhath1,2, CS Marathe1,2, MJ Bound1,2, KL Jones1,2, M Horowitz1,2 and CK Rayner1,2
The region of enteral nutrient exposure may be an important determinant of postprandial incretin hormone secretion and blood
glucose homoeostasis. We compared responses of plasma glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic
polypeptide (GIP), insulin and glucagon, and blood glucose to a standardised glucose infusion into the proximal jejunum and
duodenum in healthy humans. Ten healthy males were evaluated during a standardised glucose infusion (2 kcal min− 1 over
120min) into the proximal jejunum (50 cm post pylorus) and were compared with another 10 healthy males matched for ethnicity,
age and body mass index who received an identical glucose infusion into the duodenum (12 cm post pylorus). Blood was sampled
frequently for measurements of blood glucose and plasma hormones. Plasma GLP-1, GIP and insulin responses, as well as the
insulin:glucose ratio and the insulinogenic index 1 (IGI1) were greater (Po0.05 for each) after intrajejunal (i.j.) than intraduodenal
glucose infusion, without a signiﬁcant difference in blood glucose or plasma glucagon. Pooled analyses revealed direct
relationships between IGI1 and the responses of GLP-1 and GIP (r= 0.48 and 0.56, respectively, Po0.05 each), and between
glucagon and GLP-1 (r= 0.70, Po0.001). In conclusion, i.j. glucose elicits greater incretin hormone and insulin secretion than
intraduodenal glucose in healthy humans, suggesting regional speciﬁcity of the gut–incretin axis.
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INTRODUCTION
Roux-en-Y gastric bypass leads to remarkable improvements in
glycaemic control in type 2 diabetes, associated with an enhanced
incretin effect (the phenomenon of an ampliﬁed insulin response
to enteral vs intravenous (i.v.) glucose, mediated by glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypep-
tide (GIP)).1,2 This may relate to diversion of nutrients more distally
in the small intestine, as similar beneﬁts are observed with the
endoluminal sleeve device.3 We hypothesised that bypassing the
duodenum would elicit a greater response of the gut–incretin axis
to small intestinal glucose infusion, and compared plasma GLP-1,
GIP, insulin and glucagon, and blood glucose responses to
a standardised glucose infusion into the proximal jejunum and
duodenum in healthy humans.
SUBJECTS AND METHODS
Ten healthy males received an intrajejunal (i.j.) glucose infusion;
data regarding blood glucose, and plasma insulin, glucagon and
GLP-1 have been reported previously.4 These, together with
plasma GIP, were compared with 10 healthy males who received
an intraduodenal (i.d.) glucose infusion (Table 1). All subjects
provided written, informed consent. Protocols were approved by
the Royal Adelaide Hospital Human Research Ethics Committee.
On the evening before each study (~1900 hours), each subject
consumed a standardised beef lasagne meal (McCain, Wendouree,
VIC, Australia), and then fasted from solids and refrained from
liquids after 2200 hours. Subjects attended the laboratory at
~ 0800 hours the following day, when a multilumen silicone
catheter (Dentsleeve International, Ontario, Canada) was posi-
tioned transnasally in either the duodenum or proximal jejunum
(infusion port: 12 vs 50 cm beyond the pylorus) by peristalsis, with
monitoring of antral and duodenal transmucosal potential
difference.4 In the i.j. study, a balloon was inﬂated 30 cm beyond
the pylorus to exclude the duodenum.4 Enteral glucose was then
infused at 2 kcal min− 1 for 120min (t= 0–120min). An i.v. cannula
was inserted into a forearm vein for blood sampling. Blood
samples were collected at frequent intervals into ice-chilled EDTA
tubes and immediately centrifuged at 3200 r.p.m., for 15min at 4 °C.
Plasma was separated and stored at − 70 °C until analysed.
Blood glucose was measured by glucometer (Medisense
Precision QID, Bedford, MA, USA). Plasma total GLP-1 was
measured by radioimmunoassay (GLP1T-36HK; Linco Research,
St Charles, MO, USA) with a sensitivity of 3 pmol l− 1, and intra- and
inter-assay coefﬁcients of variation (CVs) of 6.8% and 8.5%,
respectively. Plasma total GIP was measured by radioimmunoas-
say modiﬁed from a previously published method,5 with
a sensitivity of 2 pmol l− 1, and intra- and inter-assay CVs of 5.1%
and 8.8%, respectively. Plasma insulin was measured by enzyme-
linked immunosorbent assay (10-1113; Mercodia, Uppsala,
Sweden) with a sensitivity of 1 mU l− 1 and intra- and inter-assay
CVs of 2.7% and 7.8%, respectively. Plasma glucagon was
measured by radioimmunoassay (GL-32 K; Millipore, Billerica, MA,
USA) with a sensitivity of 20 pgml− 1, and intra- and inter-assay
CVs of 15% and 10.5%, respectively.
Student’s unpaired t-test was used to compare subject
demographics, fasting biochemical measures and insulinogenic
index 1 (IGI1), which was calculated from insulin (I) and glucose (G)
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concentrations, as (I30-I0)/(G30-G0), to evaluate β-cell responsiveness.
6
Two-way analysis of variance, with treatment and time as factors,
was used to compare responses between the two studies.
Pearson’s correlation was used to assess relationships between
integrated area under the curve (ΔAUC), calculated using the
trapezoidal rule, for incretin hormones and both IGI1 and ΔAUC
for glucagon. Analyses were performed using Prism 6.0 software
(GraphPad, La Jolla, CA, USA). Data are represented as mean± s.e.;
Po0.05 (two sided) was considered statistically signiﬁcant.
RESULTS
Demographics and fasting values did not differ between the two
studies (Table 1). During enteral glucose infusion, plasma GLP-1
increased substantially with i.j. administration (time effect:
Po0.001), but minimally with i.d. delivery (time effect:
P= 0.003), and was greater for i.j. than i.d. glucose (treatment
effect: P= 0.037). Plasma GIP increased promptly on both days
(time effect: Po0.001), and concentrations were also greater with
i.j. glucose (treatment effect: P= 0.017). Blood glucose concentra-
tions increased to ~ 8mmol l− 1 on both days, and were
numerically, but not signiﬁcantly, lower with i.j. glucose. However,
plasma insulin, the insulin:glucose ratio and IGI1 (12.0 ± 1.4 vs
5.6 ± 1.3 mUmmol− 1) were all greater with i.j. glucose (treatment
effect: Po0.05 for all). Plasma glucagon did not change with i.j.
glucose, but fell slightly with i.d. glucose (time effect: Po0.001),
without signiﬁcant difference between the two (Figure 1).
On pooling data from all 20 subjects, IGI1 was related directly to
ΔAUC for total GLP-1 and GIP (r= 0.48, P= 0.036 and r= 0.56,
P= 0.012, respectively). ΔAUC for glucagon was related directly to
ΔAUC for GLP-1 (r= 0.70, Po0.001), but not GIP.
CONCLUSION
We showed that i.j. glucose elicited greater incretin and insulin
release than i.d. glucose in healthy males, supporting the concept
that directing nutrients more distally in the small intestine could
ameliorate type 2 diabetes. Blood glucose did not differ
signiﬁcantly, probably because of the modest glycaemic excursion
in these healthy individuals. However, we cannot rule out a type 2
error due to the small size of each group.
Enteral glucose was delivered at 2 kcal min− 1 on both days,
which is within the physiological range of gastric emptying.7 The
infusion site was 38 cm more distal in the i.j. study; given that the
small intestine can absorb glucose at 2 kcal min− 1 per 30 cm in
health,8,9 this would have allowed substantially greater interaction
of glucose with more distal gut regions where GLP-1-releasing
L-cells are more abundant. This is consistent with observations of
enhanced GLP-1 secretion after implantation of a duodenal-jejunal
sleeve.3 Alternatively, exclusion of the duodenum may have a role
in ameliorating diabetes (the ‘foregut hypothesis’).10 The relative
contribution of more distal gut exposure vs duodenal exclusion
should be evaluated in subsequent studies. The greater GIP
response to i.j. glucose may also reﬂect a higher density of GIP
secreting K-cells in the proximal jejunum than duodenum in
humans, as seen in pigs.11 Moreover, the expression of sodium
glucose co-transporter-1 may be of relevance12—this was
reported to be greater in the jejunum than duodenum in
rodents.13
Plasma glucagon decreased during i.d. glucose infusion, but
remained unchanged during i.j. glucose infusion. This may be
partly accounted for by the interplay between GLP-1 and GIP on
pancreatic α-cells; the glucagonostatic effect of GLP-1 is blunted,14
and the glucagonotropic effect of GIP is potentiated,15 in the
context of relatively low blood glucose concentrations. Surpris-
ingly, a direct relationship between glucagon and GLP-1 was
observed, which might imply a contribution of GLP-2, a hormone
co-secreted with GLP-1 and potent at stimulating glucagon.16
Differences in glucagon between the i.d. and i.j. studies may have
contributed to the lack of difference in blood glucose
concentrations.
We inﬂated a balloon in the i.j. study to exclude the duodenum;
this per se would be unlikely to enhance incretin secretion.17
Exclusion of bile in the i.j. study would not affect GIP secretion,18
and if anything would favour a reduced GLP-1 response.4 In the
i.d. study, it is possible that some of the infused glucose could
have reﬂuxed into the stomach, but this should have been
minimised by the increased pyloric tone associated with i.d.
glucose infusion.19
Our study has limitations, which should be recognised. First,
our observations were made in a parallel study design, with
a relatively small number of subjects in each group; however, the
subjects were well matched and the differences in plasma incretin
hormones and insulin were consistent between the two studies.
Therefore, increasing the sample size in a crossover study is
unlikely to alter the study conclusions. Furthermore, small
intestinal glucose was delivered into two sites at a single rate. It
would be of interest to employ different rates of glucose infusion
into various sites in order better to characterise the regional
speciﬁcity of the gut–incretin axis. Finally, the balance of evidence
seems to suggest alterations in secretion and/or action of incretin
hormones in obesity and type 2 diabetes.20 For example, the
secretion of GLP-1 is reportedly impaired in obesity, while GIP
secretion may be enhanced.20 In the case of type 2 diabetes, the
insulinotropic effect of GIP is largely diminished, although that of
GLP-1 is better preserved. These pathophysiological features
warrant further evaluation of the gut–incretin physiology in the
presence of obesity and/or type 2 diabetes.
In summary, our observations indicate that i.j. glucose elicits
greater incretin hormone and insulin secretion than i.d. glucose in
healthy humans, suggesting regional speciﬁcity of the gut–
incretin axis.
Table 1. Demographics and fasting biochemical measures of subjects in the intrajejunal (i.j.) vs intraduodenal (i.d.) studya
i.j. study i.d. study
Subjects 10 healthy males (8 Caucasians and 2 Asians) 10 healthy males (8 Caucasians and 2 Asians)
Age (years) 33.4± 6.0 33.4± 5.3
BMI (kgm− 2) 24.5± 1.1 25.0± 1.0
Fasting glucose (mmol l− 1) 5.0± 0.1 5.4± 0.1
Fasting insulin (mU l− 1) 3.1± 0.4 2.5± 0.5
Fasting insulin:glucose ratio (mUmmol − 1) 0.6± 0.1 0.5± 0.1
Fasting GLP-1 (pmol l− 1) 19.2± 2.0 24.1± 2.4
Fasting GIP (pmol l− 1) 14.0± 1.6 15.3± 2.7
Fasting glucagon (pgml− 1) 54.9± 7.9 52.5± 2.6
Abbreviations: BMI, body mass index; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1. aData are represented as mean± s.e.;
Student's unpaired t-test was used to determine the statistical signiﬁcance. Po0.05 was considered statistically signiﬁcant.
Regional speciﬁcity of incretin release
T Wu et al
2
Nutrition & Diabetes (2015) 1 – 4
CONFLICT OF INTEREST
The study was supported by the National Health and Medical Research Council
(NHMRC) project grant (No. APP1066815). TW has received research funding from
AstraZeneca. CKR has received research funding from Merck, Eli Lilly and Novartis.
MH has participated in the advisory boards and/or symposia for Novo Nordisk, Sanoﬁ,
Novartis, Eli Lilly, Merck Sharp & Dohme, Boehringer Ingelheim and AstraZeneca, and
has received honoraria for his activity. KLJ’s salary is provided by an NHMRC Senior
Career Development Award (627011). The remaining authors declare no conﬂict of
interest.
ACKNOWLEDGEMENTS
We wish to thank Ms Kylie Lange (Centre of Research Excellence in Translating
Nutritional Science to Good Health, University of Adelaide) for her expert statistical
advice.
AUTHOR CONTRIBUTIONS
TW was involved in the conception of the study, the study design and
coordination, subject recruitment, data collection and interpretation, statistical
analysis and drafting of the manuscript; SST and CSM were involved in
data collection and interpretation, and drafting of the manuscript; MJB assisted
data collection; MH and KLJ were involved in conception of the study and data
interpretation; CKR was involved in conception and design of the study, data
interpretation. All authors critically reviewed the manuscript, and have
approved the publication of the ﬁnal version of the manuscript.
REFERENCES
1 Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A et al. Effect of
weight loss by gastric bypass surgery versus hypocaloric diet on glucose and
incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93:
2479–2485.
2 Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J et al. Incretin levels and
effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in
obese patients with type 2 diabetes. Diabetes Care 2007; 30: 1709–1716.
3 de Jonge C, Rensen SS, Verdam FJ, Vincent RP, Bloom SR, Buurman WA et al.
Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes
Surg 2013; 23: 1354–1360.
4 Wu T, Bound MJ, Standﬁeld SD, Jones KL, Horowitz M, Rayner CK. Effects of
taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to
small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab 2013;
98: E718–E722.
5 Wishart J, Morris HA, Horowitz M. Radioimmunoassay of gastric inhibitory
polypeptide in plasma. Clin Chem 1992; 38: 2156–2157.
6 Herzberg-Schafer SA, Staiger H, Heni M, Ketterer C, Guthoff M, Kantartzis K et al.
Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin
Figure 1. Comparative responses of plasma total GLP-1 (a), total GIP (b), blood glucose (c), plasma insulin (d), the insulin:glucose ratio (e) and
plasma glucagon (f) during an intrajejunal (i.j.) and intraduodenal (i.d.) glucose infusion at the rate of 2 kcal min− 1 (t= 0–120min) in healthy
males (n= 10 each). P-values are for (A): differences by experiment, (B) differences over time and (AB): differences due to the interaction of
experiment and time. Data are represented as mean± s.e.; Po0.05 was considered statistically signiﬁcant.
Regional speciﬁcity of incretin release
T Wu et al
3
Nutrition & Diabetes (2015) 1 – 4
release for the detection of genetically impaired beta-cell function. PLoS One
2010; 5: e14194.
7 Brener W, Hendrix TR, McHugh PR. Regulation of the gastric emptying of glucose.
Gastroenterology 1983; 85: 76–82.
8 Duchman SM, Ryan AJ, Schedl HP, Summers RW, Bleiler TL, Gisolﬁ CV. Upper limit
for intestinal absorption of a dilute glucose solution in men at rest. Med Sci Sports
Exerc 1997; 29: 482–488.
9 Modigliani R, Bernier JJ. Absorption of glucose, sodium, and water by the human
jejunum studied by intestinal perfusion with a proximal occluding balloon and at
variable ﬂow rates. Gut 1971; 12: 184–193.
10 Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal
model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004;
239: 1–11.
11 Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a
subset of endocrine cells in the small intestine. Regul Pept 2003; 114: 189–196.
12 Wu T, Zhao BR, Bound MJ, Checklin HL, Bellon M, Little TJ et al. Effects of different
sweet preloads on incretin hormone secretion, gastric emptying, and post-
prandial glycemia in healthy humans. Am J Clin Nutr 2012; 95: 78–83.
13 Woyengo TA, Rodriguez-Lecompte JC, Adeola O, Nyachoti CM. Histomorphology
and small intestinal sodium-dependent glucose transporter 1 gene expression in
piglets fed phytic acid and phytase-supplemented diets. J Anim Sci 2011; 89:
2485–2490.
14 Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R et al. Effects of
glucagon-like peptide 1 on counterregulatory hormone responses, cognitive func-
tions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp
experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239–1246.
15 Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE et al. Gastric
inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in
healthy human subjects at euglycaemia. Diabetologia 2003; 46: 798–801.
16 Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K et al. Glucagon-like
peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits
gastric acid secretion in humans. Gastroenterology 2006; 130: 44–54.
17 Little TJ, Doran S, Meyer JH, Smout AJ, O'Donovan DG, Wu KL et al. The release of
GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length
of small intestine exposed. Am J Physiol Endocrinol Metab 2006; 291: E647–E655.
18 Bjornsson OG, Fletcher DR, Christoﬁdes ND, Bloom SR, Chadwick VS. Duodenal
perfusion with sodium taurocholate inhibits biliary but not pancreatic secretion in
man. Clin Sci (Lond) 1982; 62: 651–659.
19 Rayner CK, Schwartz MP, van Dam PS, Renooij W, de Smet M, Horowitz M et al.
Upper gastrointestinal responses to intraduodenal nutrient in type 1 diabetes
mellitus. Eur J Gastroenterol Hepatol 2004; 16: 183–189.
20 Deacon CF, Ahren B. Physiology of incretins in health and disease. Rev Diabet Stud
2011; 8: 293–306.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
Regional speciﬁcity of incretin release
T Wu et al
4
Nutrition & Diabetes (2015) 1 – 4
